Liraglutide and semaglutide reduce MACE in diabetes patients regardless of PAD status: Study Medha Baranwal21 April 2022 3:30 AM GMTDenmark: Liraglutide and semaglutide may reduce major adverse cardiovascular events (MACE) in type 2 diabetes (T2D) patients regardless of their...
Quantitative CMR may independently Predict Adverse Outcomes in In patients with Prior CABG MD Bureau13 April 2022 4:30 AM GMTPatients with previous coronary artery bypass graft (CABG) surgery typically have complex coronary disease and remain at high risk of adverse events....
Sotagliflozin tied to reduced risk of MACE in patients with diabetes and CKD: SCORED Trial Medha Baranwal5 April 2022 5:45 AM GMTUSA: Results from SCORED trial sheds light on the potent effect of the investigational SGLT1&2 inhibitor sotagliflozin on major cardiovascular...
Clopidogrel Bests Aspirin for Secondary Prevention of ASCVD MD Bureau1 April 2022 5:15 AM GMTAntiplatelet therapy is the cornerstone for the prevention and treatment of atherothrombosis. Aspirin is the most widely used antiplatelet agent for...
Colchicine cheap and low-risk medication to reduce MACE in patients undergoing PCI: BMJ Medha Baranwal11 Feb 2022 3:30 AM GMTUK: A recent study showed that colchicine significantly reduces MACE risk in coronary artery disease (CAD) patients who underwent percutaneous...
Stress CMR-inducible MI and LGE may predict MACE in HFpEF patients without CAD: Study Medha Baranwal29 Dec 2021 3:30 AM GMTFrance: A recent study found that stress cardiovascular magnetic resonance (CMR)-inducible myocardial ischemia and late gadolinium enhancement (LGE)...
Treatment with DPP-4i versus sulphonylureas yield similar MACE risk in type 2 diabetics: Study Medha Baranwal20 Dec 2021 4:15 AM GMTUK: Type 2 diabetes (T2D) patients treated with DPP-4 inhibitors versus sulphonylureas as add-on to metformin has a similar risk of cardiovascular...
Time to Rethink about routine oral Anti-platelet therapy before PCI for Non-ST-Elevated ACS? MD Bureau24 Nov 2021 3:30 AM GMTThe timing of oral P2Y12 inhibitor administration in patients with non-ST elevation acute coronary syndromes (NSTEACS) has been a matter of...
Type 2 diabetes patients with polyvascular disease at increased risk of MACE: EXSCEL trial Medha Baranwal4 Nov 2021 4:15 AM GMTUSA: The risk of MACE and mortality increases incrementally with each additional diseased arterial bed in patients with type 2 diabetes versus those...
LDL-C level reduction <25 mg/dL with alirocumab not tied to MACE reduction: Circulation Medha Baranwal29 Jan 2021 3:57 PM GMTUSA: Acute coronary syndrome (ACS) patients treated with alirocumab who achieved LDL-C levels <25 mg/dL versus 25–50 mg/d did not show any...
Semaglutide reduces major adverse CV event risk in Diabetics with raised triglycerides MD Bureau1 Jan 2021 11:45 AM GMTA posthoc analysis on SUSTAIN 6 and PIONEER 6 trial showed semaglutide was associated with consistent reduction in major Adverse cardiovascular event...
Metformin significantly lowers death risk due to cardiac and other causes: Study Medha Baranwal14 Dec 2020 7:15 AM GMTItaly: Compared to other anti-hyperglycaemic drugs or placebo, the use of metfomin significantly lowers the mortality risk and MACE risk in patients...
